Phase I/II Trial of the Combination of Midostaurin (PKC412) and 5-Azacytidine for Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

We investigated the combination of midostaurin and azacitidine (AZA) in patients with AML and high risk MDS. Patients received AZA 75 mg/m(2) on days 1–7 and midostaurin 25 mg bid (in cohort 1 of phase I) or 50 mg bid (in cohort 2 of Phase I and in Phase II) orally on day 8–21 during the first cycle...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Hematol
Autori principali: Strati, Paolo, Kantarjian, Hagop, Ravandi, Farhad, Nazha, Aziz, Borthakur, Gautam, Daver, Naval, Kadia, Tapan, Estrov, Zeev, Garcia-Manero, Guillermo, Konopleva, Marina, Rajkhowa, Trivikram, Durand, Menda, Andreeff, Michael, Levis, Mark, Cortes, Jorge
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4376596/
https://ncbi.nlm.nih.gov/pubmed/25530214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23924
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi